Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06528405
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-25
Brief Title:
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ESS-AKD
Brief Summary:
Acute kidney disease AKD happens between 7 and 90 days after an initial kidney injury AKI This period is crucial because it can determine whether the condition worsens into chronic kidney disease CKD Despite knowing this there is no proven treatment to improve outcomes for people with AKD
Recent studies have shown that drugs called sodium-glucose cotransporter 2 SGLT2 inhibitors can slow down the worsening of chronic kidney disease help with heart failure and reduce the risk of death Now researchers are looking into whether these drugs can also help prevent acute kidney injury AKI and improve outcomes for AKD patients
Our project will explore the use of SGLT2 inhibitors in patients with AKD with the belief that these drugs can safely reduce the amount of protein albumin in the urine and improve kidney health To address this investigators plan to conduct a large multicenter study in Taiwan This study will be randomized and placebo-controlled meaning some patients will receive the SGLT2 inhibitors while others will receive a placebo a harmless inactive substance Investigators will include AKD patients with and without diabetes focusing on reducing the protein in their urine and monitoring for any serious side effects
The goal of this trial is to provide strong evidence on whether SGLT2 inhibitors can be an effective treatment for AKD If successful this could offer a new strategy to prevent the progression from AKI to CKD and improve the health and outcomes of patients with kidney disease
Recent studies have shown that drugs called sodium-glucose cotransporter 2 SGLT2 inhibitors can slow down the worsening of chronic kidney disease help with heart failure and reduce the risk of death Now researchers are looking into whether these drugs can also help prevent acute kidney injury AKI and improve outcomes for AKD patients
Our project will explore the use of SGLT2 inhibitors in patients with AKD with the belief that these drugs can safely reduce the amount of protein albumin in the urine and improve kidney health To address this investigators plan to conduct a large multicenter study in Taiwan This study will be randomized and placebo-controlled meaning some patients will receive the SGLT2 inhibitors while others will receive a placebo a harmless inactive substance Investigators will include AKD patients with and without diabetes focusing on reducing the protein in their urine and monitoring for any serious side effects
The goal of this trial is to provide strong evidence on whether SGLT2 inhibitors can be an effective treatment for AKD If successful this could offer a new strategy to prevent the progression from AKI to CKD and improve the health and outcomes of patients with kidney disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None